News
Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.
The Food and Drug Administration restored a top vaccine regulator to his position at the agency just weeks after firing him.
Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...
Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...
BTIG analyst Thomas Shrader maintained a Hold rating on Inmune Bio ( INMB – Research Report) yesterday. The company’s shares closed yesterday at $2.31. Take advantage of TipRanks Premium at 50% off!
1d
TipRanks on MSNNovavax Stock Surges Amid Strategic GainsNovavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...
In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novavax, with a price target of $8.00. The company’s shares closed yesterday at $7.58. Elevate ...
A research study from the United States suggests that bird flu could have spread amongst cattle through the air or ...
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...
Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...
SHREVEPORT, La. - The U.S. Department of Health and Human Services has announced $500 million in funding cuts to vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results